Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease.
Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease.
复制标题
DOI：
10.1001/archneurol.2012.1070
复制
发表时间：
2012-10
影响因子：
--
通讯作者：
Shaw, Leslie M.
中科院分区：
文献类型：
--
作者：
Soares, Holly D.;Potter, William Z.;Pickering, Eve;Kuhn, Max;Immermann, Frederick W.;Shera, David M.;Ferm, Mats;Dean, Robert A.;Simon, Adam J.;Swenson, Frank;Siuciak, Judith A.;Kaplow, June;Thambisetty, Madhav;Zagouras, Panayiotis;Koroshetz, Walter J.;Wan, Hong I.;Trojanowski, John Q.;Shaw, Leslie M.
基于血液的测试可以用作阿尔茨海默病（AD）的筛查，可以实现早期干预和更好地获得治疗。采用阿尔茨海默病神经影像学倡议队列的血浆样本，应用多重免疫测定组鉴定AD的血浆生物标志物。队列研究。生物标记联盟阿尔茨海默病血浆蛋白质组学项目。分析了396例（1年时345例）轻度认知障碍患者、112例（1年时97例）AD患者和58例（1年时54例）健康对照受试者基线和1年时的血浆样本。多变量和单变量统计分析用于检查诊断组之间的差异以及与载脂蛋白E（ApoE）基因型相关的差异。在患者中观察到嗜酸性粒细胞趋化因子3、胰腺多肽和N末端蛋白B型脑钠肽水平升高，证实了AD和MCI患者脑脊液样本中报告的相似变化。还观察到腱生蛋白C水平增加以及IgM和ApoE水平降低。所有携带Apo ε3/ε4或ε4/ε4等位基因的受试者均表现出明显的生化特征，其特征为C反应蛋白和ApoE水平较低，皮质醇、白细胞介素13、载脂蛋白B和γ干扰素水平较高。血浆生物标志物的使用提高了区分AD患者与对照组的特异性，轻度认知障碍进展为痴呆的患者的ApoE血浆水平最低。血浆生物标志物结果证实了脑脊液研究报告的AD和轻度认知障碍患者中胰多肽和N末端蛋白B型脑钠肽水平升高。血浆生物标志物的掺入产生了高灵敏度和改进的特异性，支持其作为筛选工具的有用性。ApoE基因型与一个独特的生化谱，无论诊断，强调基因型的血液蛋白谱的重要性。
A blood-based test that could be used as a screen for Alzheimer disease (AD) may enable early intervention and better access to treatment. To apply a multiplex immunoassay panel to identify plasma biomarkers of AD using plasma samples from the Alzheimer’s Disease Neuroimaging Initiative cohort. Cohort study. The Biomarkers Consortium Alzheimer’s Disease Plasma Proteomics Project. Plasma samples at baseline and at 1 year were analyzed from 396 (345 at 1 year) patients with mild cognitive impairment, 112 (97 at 1 year) patients with AD, and 58 (54 at 1 year) healthy control subjects. Multivariate and univariate statistical analyses were used to examine differences across diagnostic groups and relative to the apolipoprotein E (ApoE) genotype. Increased levels of eotaxin 3, pancreatic polypeptide, and N-terminal protein B–type brain natriuretic peptide were observed in patients, confirming similar changes reported in cerebrospinal fluid samples of patients with AD and MCI. Increases in tenascin C levels and decreases in IgM and ApoE levels were also observed. All participants with Apo ε3/ε4 or ε4/ε4 alleles showed a distinct biochemical profile characterized by low C-reactive protein and ApoE levels and by high Cortisol, interleukin 13, apolipoprotein B, and gamma interferon levels. The use of plasma biomarkers improved specificity in differentiating patients with AD from controls, and ApoE plasma levels were lowest in patients whose mild cognitive impairment had progressed to dementia. Plasma biomarker results confirm cerebrospinal fluid studies reporting increased levels of pancreatic polypeptide and N-terminal protein B–type brain natriuretic peptide in patients with AD and mild cognitive impairment. Incorporation of plasma biomarkers yielded high sensitivity with improved specificity, supporting their usefulness as a screening tool. The ApoE genotype was associated with a unique biochemical profile irrespective of diagnosis, highlighting the importance of genotype on blood protein profiles.
登录
查看更多内容
影响因子：
3.7
作者：
Bruno, Davide;Nierenberg, Jay J.;Ritchie, James C.;Lutz, Michael W.;Pomara, Nunzio
通讯作者：
Pomara, Nunzio
影响因子：
4.2
作者：
Ewers M;Walsh C;Trojanowski JQ;Shaw LM;Petersen RC;Jack CR Jr;Feldman HH;Bokde AL;Alexander GE;Scheltens P;Vellas B;Dubois B;Weiner M;Hampel H;North American Alzheimer's Disease Neuroimaging Initiative (ADNI)
通讯作者：
North American Alzheimer's Disease Neuroimaging Initiative (ADNI)
影响因子：
3.9
作者：
Ewers, Michael;Mielke, Michelle M.;Hampel, Harald
通讯作者：
Hampel, Harald
DOI：
10.1016/j.jalz.2011.03.005
发表时间：
2011-05
期刊：
Alzheimer's & dementia : the journal of the Alzheimer's Association
影响因子：
--
作者：
McKhann GM;Knopman DS;Chertkow H;Hyman BT;Jack CR Jr;Kawas CH;Klunk WE;Koroshetz WJ;Manly JJ;Mayeux R;Mohs RC;Morris JC;Rossor MN;Scheltens P;Carrillo MC;Thies B;Weintraub S;Phelps CH
通讯作者：
Phelps CH
影响因子：
14.5
作者：
Hye, A.;Lynham, S.;Lovestone, S.
通讯作者：
Lovestone, S.